This narrative review article summarizes past and current technologies for generating
antibodies for passive immunization/immunotherapy. Contemporary DNA and protein …

Abstract The Global Action Plan for influenza vaccines (GAP) aims to increase the
production capacity of vaccines so that in the event of a pandemic there is an adequate …

Background Current influenza virus vaccines are effective when well matched to the
circulating strains. Unfortunately, antigenic drift and the high diversity of potential emerging …

Control programs for emerging influenza are in urgent need of novel therapeutic strategies
to mitigate potentially devastating threats from pathogenic strains with pandemic potential …

Passive immunization using antibodies is a promising alternative to other antiviral treatment
options. The potential for seasonal protection arising from a single injection of antibodies is …

The natural human antibody response is a rich source of highly specific, neutralizing and
self-tolerant therapeutic reagents. Recent advances have been made in isolating and …

Highlights•Broadly neutralizing antibodies against influenza A and B represents a safe and
affordable alternative to convalescent plasma.•The large majority of broadly neutralizing …

Influenza is a disease that poses a significant health burden worldwide. Vaccination is the
best way to prevent influenza virus infections. However, conventional vaccines are only …

Most currently used conventional influenza vaccines are based on 1940s technology.
Advances in vaccine immunogen design and delivery emerging over the last decade …

Influenza virus is a respiratory pathogen that can cause disease in humans, with symptoms
ranging from mild to life-threatening. The vast majority of influenza virus infections in …